HYTN receives GMP certificates for the United States, Bermuda and Israel

HYTN Innovations has received digital Good Manufacturing Practices (GMP) certificates from Health Canada confirming the GMP compliance of its Kelowna-based manufacturing facility. Issued under HYTN's Drug Establishment Licence these Certificates specifically acknowledge the Company's GMP status for the United States, Bermuda, and Israel.

The Certificates, requested by HYTN in February, are important for drug registrations in jurisdictions where they apply. They also provide assurance in regions with limited regulatory frameworks, validating that HYTN's production processes meet GMP standards. Notably, the Company's DEL enables it to fabricate, package, and label non-sterile pharmaceuticals containing cannabis and psilocybin, positioning HYTN at the forefront of international markets looking to expand their pharmaceutical offerings.

"By demonstrating GMP compliance in markets that require it, HYTN is well-positioned to support new drug registrations, facilitate clinical trials, and offer contract manufacturing for both cannabis and psilocybin-based pharmaceuticals," said Jason Broome, COO of HYTN. "Our continued commitment to GMP manufacturing strengthens our ability to evaluate global opportunities while driving value for partners and stakeholders alike."